tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

AQST Stock Latest News

Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
RatingsBuy Rating for Aquestive Therapeutics Driven by Anaphylm’s FDA Approval Prospects and Market Potential
6d ago
AQST
Aquestive Therapeutics price target raised to $8 from $5 at Piper Sandler
PremiumThe Fly
Aquestive Therapeutics price target raised to $8 from $5 at Piper Sandler
9d ago
AQST
Aquestive Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Aquestive Therapeutics Reports Q3 2025 Financial Results
9d ago
AQST
Aquestive Therapeutics’ Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
Aquestive Therapeutics’ Earnings Call: Optimism Amid Challenges
9d ago
AQST
Aquestive Therapeutics Advances Anaphylm Towards FDA Approval
PremiumCompany Announcements
Aquestive Therapeutics Advances Anaphylm Towards FDA Approval
10d ago
8K
AQST
Positive Outlook for Aquestive Therapeutics: Buy Rating Driven by Strong Pipeline, Financial Position, and Upcoming PDUFA Date
PremiumRatingsPositive Outlook for Aquestive Therapeutics: Buy Rating Driven by Strong Pipeline, Financial Position, and Upcoming PDUFA Date
10d ago
AQST
Aquestive Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Aquestive Therapeutics Reports Q3 2025 Financial Results
11d ago
8K
AQST
Aquestive Therapeutics reports Q3 EPS (14c), consensus (11c)
Premium
The Fly
Aquestive Therapeutics reports Q3 EPS (14c), consensus (11c)
11d ago
AQST
Aquestive Therapeutics cuts FY25 revenue view to $44M-$50M from $47M-$56M
PremiumThe Fly
Aquestive Therapeutics cuts FY25 revenue view to $44M-$50M from $47M-$56M
11d ago
AQST
Aquestive Therapeutics options imply 14.6% move in share price post-earnings
PremiumThe Fly
Aquestive Therapeutics options imply 14.6% move in share price post-earnings
11d ago
AQST
Aquestive appoints Davis as CDO, Slatko as interim CMO, Boyd as CPO
PremiumThe Fly
Aquestive appoints Davis as CDO, Slatko as interim CMO, Boyd as CPO
12d ago
AQST
Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
PremiumThe Fly
Aquestive Therapeutics price target raised to $12 from $9 at Citizens JMP
1M ago
AQST
Aquestive Therapeutics Secures New Patents for Anaphylm
PremiumCompany AnnouncementsAquestive Therapeutics Secures New Patents for Anaphylm
1M ago
8K
AQST
Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
Premium
The Fly
Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
1M ago
AQST
Aquestive Therapeutics Advances Anaphylm Clinical Development
Premium
Company Announcements
Aquestive Therapeutics Advances Anaphylm Clinical Development
2M ago
8K
AQST
Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
PremiumWeekend Updates
Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
2M ago
TKO
AQST
Aquestive Therapeutics Highlights at Global Investor Conference
PremiumCompany Announcements
Aquestive Therapeutics Highlights at Global Investor Conference
2M ago
8K
AQST
Aquestive Therapeutics price target raised to $8 from $7 at Oppenheimer
PremiumThe Fly
Aquestive Therapeutics price target raised to $8 from $7 at Oppenheimer
2M ago
AQST
Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy Market
PremiumRatings
Aquestive Therapeutics: De-risking and Strategic Positioning for Success in the Type 1 Allergy Market
2M ago
AQST
Salesforce slides, Figma flops after earnings: Morning Buzz
PremiumThe FlySalesforce slides, Figma flops after earnings: Morning Buzz
2M ago
AI
GS
Buy Rating Reiterated for Aquestive Therapeutics: Favorable FDA Outlook and Strong Market Potential for Anaphylm
Premium
Ratings
Buy Rating Reiterated for Aquestive Therapeutics: Favorable FDA Outlook and Strong Market Potential for Anaphylm
2M ago
AQST
Aquestive Therapeutics Awaits FDA Decision on Anaphylm
Premium
Company Announcements
Aquestive Therapeutics Awaits FDA Decision on Anaphylm
2M ago
8K
AQST

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >